CG
SEEL

Cutler Group’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Cutler Group’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Hold
0
– – – 4515
2023
Q3 		– Hold
0
– – – 4450
2023
Q2 		– Hold
0
– – – 4318
2023
Q1 		– Hold
0
– – – 4904
2022
Q4 		– Sell
-1
Closed -$3.49K – 4215
2022
Q3 		$4K Hold
1
– – ﹤0.01% 3878
2022
Q2 		$2K Hold
1
– – ﹤0.01% 4417
2022
Q1 		$3K Buy
+1
New +$4.3K ﹤0.01% 4562
2021
Q3 		– Hold
0
– – – 6526
2021
Q2 		– Sell
-2
Closed -$32.9K – 6528
2021
Q1 		$29K Buy
+2
New +$23.3K ﹤0.01% 2888

Other funds holding SEEL

Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cutler Group's SEEL Position: Q4 2023 in Review

Cutler Group held its Seelos Therapeutics, Inc. Common Stock (SEEL) position steady in Q4 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4515.

Cutler Group first reported a position in SEEL in Q1 2021 and has held it in 4 quarters since. The position peaked at $29K in Q1 2021. 32 funds tracked by Wall St. Rank hold SEEL as of Q4 2023.

  • Cutler Group held 0 shares of Seelos Therapeutics, Inc. Common Stock worth $0 as of Q4 2023.
  • Cutler Group left its Seelos Therapeutics, Inc. Common Stock share count unchanged in Q4 2023.
  • Seelos Therapeutics, Inc. Common Stock made up ﹤0.01% of Cutler Group's portfolio in Q4 2023, its #4515 holding.
  • Cutler Group first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2021 and has held it in 4 quarters since.
  • Cutler Group's Seelos Therapeutics, Inc. Common Stock position peaked at $29K in Q1 2021.
  • 32 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.